Nearly half of India's 10,000 drug manufacturing units might not meet the 2025 deadline for upgrading to revised Schedule M standards, risking closure. Currently, only 2,000 comply with good ...
QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael Bauer to ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...